RADX TECH - CERES NANOSCIENCE INC NANOTRAP PARTICLE MANUFACTURING

用于提取和浓缩SARS-CoV-2的纳米捕捉器颗粒的开发商Ceres Nanosciences公司已经成功地在多个实验室和环境中验证了这些颗粒的使用，以从生物溶液或废水中捕获并浓缩SARS-CoV-2，目前的水平低于现有方法的检测极限。这吸引了超过15个商业合作伙伴的兴趣，比如LabCorp，他们正在领导全国提供新冠肺炎感染诊断检测的努力。这些合作伙伴的累计需求是每天超过200万次的测试。我们目前的制造工艺不能满足这一需求，是帮助解决国家危机的瓶颈。因此，Ceres Nanosciences正在请求RADX支持，以在我们现有的质量管理体系下快速扩大NanoTrap的制造和分销，以满足合作伙伴的需求，如LabCorp，他们准备利用这项技术进行新冠肺炎感染的护理点和验证性测试。欧盟委员会正在修订数据收集和供应合同协定。

Ceres Nanosciences, developer of Nanotrap particles for extracting and concentrating SARS-CoV-2, have successfully validated the use of these particles in multiple laboratories and contexts to capture and concentrate SARS-CoV-2 from biological solutions or wastewater at levels currently below the limit of detection of existing methods. This has attracted the interest of over 15 commercial partners, such as LabCorp, who are leading the national efforts to provide diagnostic tests for COVID-19 infection. The cumulative needs for these partners are tests in excess of 2,000,000/day. Our current manufacturing processes are not able to meet this demand and represent a bottleneck to helping to address the national crisis. As such, Ceres Nanosciences is requesting RADx support to rapidly scale-up Nanotrap manufacturing and distribution under our existing quality management system to meet the demand of partners, such as LabCorp, who are poised to leverage the technology for point-of-care and confirmatory testing for COVID-19 infection. EUA amendment data collection and supply contract agreements are in process.